PDCD1 and renal cell carcinoma: Objective response rates (ORR) for advanced melanoma or renal cell carcinoma (RCC) patients treated with dual immune checkpoint blockade (anti-CTLA-4 and anti-PD-1) are 57.6% and 42%, respectively [1, 2].